ISU Abxis Co. Ltd Cash Flow Conversion Efficiency
ISU Abxis Co. Ltd cash flow conversion efficiency. Based on the latest financial reports, ISU Abxis Co. Ltd (086890) has a cash flow conversion efficiency ratio of 0.088x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩10.56 Billion ≈ $7.15 Million USD) by net assets (₩120.39 Billion ≈ $81.59 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of ISU Abxis Co. Ltd (2014–2024)
Cash flow conversion efficiency of ISU Abxis Co. Ltd from 2014 to 2024. This chart illustrates how ISU Abxis Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 086890 stock price and chart for real-time trading data and today's change.
ISU Abxis Co. Ltd Cash Flow Conversion Ratio Explained
ISU Abxis Co. Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
ISU Abxis Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ISU Abxis Co. Ltd ranked by their cash flow conversion efficiency. Also see ISU Abxis Co. Ltd stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Clime Capital Ltd
AU:CAM
|
-0.045x |
|
abrdn Asia Pacific Income Fund VCC
TO:FAP
|
0.068x |
|
Africa Energy Corp
V:AFE
|
-0.016x |
|
Titanium Oyj
HE:TITAN
|
0.222x |
|
Fine Blanking & Tool Co Ltd
TWO:4535
|
0.036x |
|
Razor Labs Ltd
TA:RZR
|
2.512x |
|
Gopeng Bhd
KLSE:2135
|
0.006x |
|
Sheetal Cool Products Limited
NSE:SCPL
|
0.030x |
Annual Cash Flow Conversion Efficiency for ISU Abxis Co. Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of ISU Abxis Co. Ltd from 2014 to 2024. Review cash generation quality of ISU Abxis Co. Ltd to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩100.86 Billion ≈ $68.35 Million |
₩2.54 Billion ≈ $1.72 Million |
0.025x | +172.20% |
| 2023-12-31 | ₩77.19 Billion ≈ $52.31 Million |
₩-2.69 Billion ≈ $-1.82 Million |
-0.035x | -459.13% |
| 2022-12-31 | ₩64.41 Billion ≈ $43.65 Million |
₩-401.66 Million ≈ $-272.20K |
-0.006x | +92.31% |
| 2021-12-31 | ₩71.95 Billion ≈ $48.76 Million |
₩-5.84 Billion ≈ $-3.96 Million |
-0.081x | +58.72% |
| 2020-12-31 | ₩43.57 Billion ≈ $29.53 Million |
₩-8.56 Billion ≈ $-5.80 Million |
-0.197x | +17.50% |
| 2019-12-31 | ₩55.18 Billion ≈ $37.40 Million |
₩-13.15 Billion ≈ $-8.91 Million |
-0.238x | -6.37% |
| 2018-12-31 | ₩59.73 Billion ≈ $40.48 Million |
₩-13.38 Billion ≈ $-9.07 Million |
-0.224x | -101.74% |
| 2017-12-31 | ₩62.05 Billion ≈ $42.05 Million |
₩-6.89 Billion ≈ $-4.67 Million |
-0.111x | -86.96% |
| 2016-12-31 | ₩45.58 Billion ≈ $30.89 Million |
₩-2.71 Billion ≈ $-1.83 Million |
-0.059x | +28.68% |
| 2015-12-31 | ₩46.59 Billion ≈ $31.57 Million |
₩-3.88 Billion ≈ $-2.63 Million |
-0.083x | +87.39% |
| 2014-12-31 | ₩17.41 Billion ≈ $11.80 Million |
₩-11.49 Billion ≈ $-7.79 Million |
-0.660x | -- |
About ISU Abxis Co. Ltd
ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long term enzyme repla… Read more